Citigroup Inc Summit Therapeutics Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 254,040 shares of SMMT stock, worth $4.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
254,040
Previous 76,135
233.67%
Holding current value
$4.89 Million
Previous $1.67 Million
171.99%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$470 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$225 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$152 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$126 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$108 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.87B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...